Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 17.9% in October

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the target of a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 6,180,000 shares, a growth of 17.9% from the September 30th total of 5,240,000 shares. Based on an average daily trading volume, of 2,880,000 shares, the days-to-cover ratio is currently 2.1 days.

Capricor Therapeutics Stock Up 2.5 %

Shares of NASDAQ:CAPR traded up $0.53 on Tuesday, reaching $21.99. 1,313,940 shares of the company's stock were exchanged, compared to its average volume of 1,150,871. Capricor Therapeutics has a fifty-two week low of $2.68 and a fifty-two week high of $23.40. The business's 50-day moving average is $11.10 and its two-hundred day moving average is $7.14. The firm has a market capitalization of $998.57 million, a price-to-earnings ratio of -22.76 and a beta of 4.01.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). The business had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. Analysts predict that Capricor Therapeutics will post -1.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of Capricor Therapeutics stock in a transaction that occurred on Friday, September 20th. The shares were purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the acquisition, the insider now owns 7,090,351 shares of the company's stock, valued at $38,004,281.36. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 12.00% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new stake in Capricor Therapeutics in the first quarter valued at $40,000. Main Street Financial Solutions LLC boosted its stake in Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock valued at $131,000 after purchasing an additional 7,500 shares during the period. SG Americas Securities LLC bought a new position in Capricor Therapeutics in the 3rd quarter worth about $133,000. Bank of New York Mellon Corp increased its stake in shares of Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock valued at $381,000 after purchasing an additional 9,040 shares during the period. Finally, Rhumbline Advisers bought a new stake in shares of Capricor Therapeutics during the second quarter valued at approximately $147,000. 21.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CAPR. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an "overweight" rating and a $35.00 target price for the company. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Oppenheimer reaffirmed an "outperform" rating and set a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Maxim Group increased their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, September 25th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $8.00 price objective on shares of Capricor Therapeutics in a report on Friday, September 20th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $24.67.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.